Sana Biotechnology
Founded in 2018, Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. The company aims to reprogram cells in the body or replace damaged ones to treat a broad range of diseases, with a pipeline including SC291, SC262, SC255, UP421, and other candidates across therapeutic areas like oncology, diabetes, autoimmune disorders, and CNS.
Top Stages
1 past transactions
Oscine Therapeutics
Acquisition in 2020
Oscine Therapeutics is a biotechnology company founded on research from the University of Rochester Medical Center. The company focuses on developing a cell therapy platform that leverages stem cell science to address central nervous system (CNS) diseases. Oscine Therapeutics generates bipotential astrocyte-oligodendrocyte glial progenitor cells, which are designed to replace lost, damaged, or dysfunctional glial cells in patients suffering from degenerative diseases and conditions affecting white matter. By advancing this innovative approach, Oscine Therapeutics aims to expand therapeutic options and enhance the potential for curing CNS diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.